Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.
about
Daptomycin in paediatrics: current knowledge and the need for future researchPopulation pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline.Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens.Association between vancomycin trough concentration and area under the concentration-time curve in neonatesPopulation pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureusVancomycin pharmacokinetics in preterm neonates and the prediction of adult clearanceTowards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling.External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings.Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children.Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?Determination of vancomycin pharmacokinetics in neonates to develop practical initial dosing recommendations.Vancomycin: a review of population pharmacokinetic analyses.Population pharmacokinetic analysis during the first 2 years of life: an overview.Quantitative clinical pharmacology for size and age scaling in pediatric drug development: A systematic review.How to use vancomycin optimally in neonates: remaining questions.Renal Function Descriptors in Neonates: Which Creatinine-Based Formula Best Describes Vancomycin Clearance?Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates.Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period.Usefulness of serum cystatin C to determine the dose of vancomycin in neonate.Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ≥400 Target.Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination.A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates.A population pharmacokinetic model for individualised dosage regimens of vancomycin in Chinese neonates and young infants.Pharmacokinetics of penicillin G in preterm and term neonates.Evaluating the Relationship between Vancomycin Trough Concentration and 24-Hour Area under the Concentration-Time Curve in Neonates.
P2860
Q27006038-0C049053-2868-40C4-A82B-CC5B0688F029Q34381352-866E396D-37BC-4AEB-A066-E8CEEE276A4BQ34442603-3D96684E-7858-4A3A-B2F2-854BF36E721EQ34596435-1BE7FBF7-C9C5-4DE6-A3C8-A304350E447FQ35127932-9B30EEFC-BF2B-45E6-BF97-B01D04B0E859Q36024899-57C1EDC0-10D2-48DF-B129-BCD04E938761Q36571794-85B02E3F-994F-45A1-A749-6CB0EE397BB8Q36729959-E7C7CB64-F98D-44A0-BC8C-DEAC868F3F0BQ37544540-15785F55-8C0C-40BC-9B24-2B2571BF376CQ37695055-4EAF9C2D-596E-42A9-8913-87B35AB16337Q37712974-51814B18-7700-4A24-83EF-CF98D7E8CFF8Q37965578-CE90BE14-8B4E-4964-B695-C72E88135062Q38062388-2663FE6B-2317-4277-AB60-6A9BA5613A92Q38502414-4205C705-DE96-43BF-837C-F7FF9C992CB5Q38569678-B16DE09F-4B24-46CA-AEC8-844408C23D1FQ38594191-D33C93D0-4414-4736-9701-6A19E871A1BEQ38696468-EC18FD0C-331B-4C81-92F2-911A4C6E00D5Q38714060-550A9906-7A4B-4BC8-A0FD-56AD3CAA6E56Q40182576-0E79CFC4-EE83-4FF2-A075-2C048B31E68DQ40327439-9ECBA494-D0DA-48E4-A176-CF8B4D436C87Q40749709-AB336BDB-D3DC-4810-AC9D-142A7B7AB06FQ41477321-92E6E949-D9F2-4419-BAD3-946A7E96CC3BQ47183620-FE521A97-8DE8-474C-BE11-80690E9543BBQ49791998-27F4D7AF-DBDD-485C-B2C6-CCA9FB83DC28Q49874675-0FD5B614-8627-4915-B52D-B79702265DF5
P2860
Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.
@en
Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.
@nl
type
label
Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.
@en
Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.
@nl
prefLabel
Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.
@en
Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.
@nl
P2093
P2860
P1476
Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.
@en
P2093
Hiroaki Kubo
Kazuo Yago
Keisuke Sunakawa
Nobuo Matsuura
Shigehiko Shimada
Toshimi Kimura
P2860
P304
P356
10.1128/AAC.48.4.1159-1167.2004
P407
P577
2004-04-01T00:00:00Z